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It has been hypothesized that IL-1a is released from damaged cardiomyocytes following
myocardial infarction (MI) and activates cardiac fibroblasts via its receptor (IL-1R1) to drive
the early stages of cardiac remodeling. This study aimed to definitively test this hypothesis
using cell type–specific IL-1a and IL-1R1–KO mouse models. A floxed Il1a mouse was
created and used to generate a cardiomyocyte-specific IL-1a–KO (MIL1AKO) mouse line. A
tamoxifen-inducible fibroblast-specific IL-1R1 hemizygous KO (FIL1R1KO) mouse line was
also generated. Mice underwent experimental MI (permanent left anterior descending
coronary artery ligation), and cardiac function was determined 4 weeks later by
conductance pressure-volume catheter analysis. Molecular markers of remodeling were
evaluated at various time points by real-time RT-PCR and histology. MIL1AKO mice
showed no difference in cardiac function or molecular markers of remodeling after MI
compared with littermate controls. In contrast, FIL1R1KO mice showed improved cardiac
function and reduced remodeling markers after MI compared with littermate controls. In
conclusion, these data highlight a key role for the IL-1R1/cardiac fibroblast signaling axis in
regulating remodeling after MI and provide support for the continued development of anti–IL-
1 therapies for improving cardiac function after MI. Cardiomyocyte-derived IL-1a was not an
important contributor to remodeling after MI in this model.
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Introduction
Although widely recognized as key regulators of  extracellular matrix (ECM) turnover, cardiac fibroblasts 
also have wide-reaching functions that are fundamental to the overall physiology and pathophysiology of  
the heart, including sensing tissue damage and contributing to cardiac inflammation (1, 2). Cardiac fibro-
blasts are particularly responsive to the proinflammatory cytokine IL-1 (3), whose levels are increased with 
many cardiovascular pathologies, including myocardial infarction (MI), cardiomyopathy, myocarditis, and 
hypertension (4, 5). In response to IL-1 stimulation, cardiac fibroblasts secrete an array of  proinflammatory 
cytokines and chemokines, and enhance ECM turnover through increased secretion of  matrix metallo-
proteinases (MMPs), decreased collagen synthesis, and decreased expression of  profibrotic cytokines (3). 
Thus, fibroblasts can contribute to the inflammatory milieu that occurs in the myocardium early post-MI, 
and the IL-1/cardiac fibroblast signaling axis is a potentially important mediator of  cardiac remodeling 
post-MI (2, 3). Furthermore, there is growing evidence to suggest that IL-1 blockade is a viable therapeutic 
strategy for treating cardiovascular disease (6–8).
IL-1 comprises 2 distinct gene products (IL-1α and IL-1β) that have generally indistinguishable biolog-
ical activities and play a significant role in the pathogenesis of  heart disease (4). Despite their similarity of  
action, IL-1α and IL-1β are produced by cells through very different mechanisms. IL-1α is an intracellular 
cytokine (nuclear and cytosolic) that is released when cells undergo necrosis and was originally shown to 
It has been hypothesized that IL-1α is released from damaged cardiomyocytes following myocardial 
infarction (MI) and activates cardiac fibroblasts via its receptor (IL-1R1) to drive the early stages of 
cardiac remodeling. This study aimed to definitively test this hypothesis using cell type–specific 
IL-1α and IL-1R1–KO mouse models. A floxed Il1a mouse was created and used to generate a 
cardiomyocyte-specific IL-1α–KO (MIL1AKO) mouse line. A tamoxifen-inducible fibroblast-specific 
IL-1R1 hemizygous KO (FIL1R1KO) mouse line was also generated. Mice underwent experimental MI 
(permanent left anterior descending coronary artery ligation), and cardiac function was determined 
4 weeks later by conductance pressure-volume catheter analysis. Molecular markers of remodeling 
were evaluated at various time points by real-time RT-PCR and histology. MIL1AKO mice showed no 
difference in cardiac function or molecular markers of remodeling after MI compared with littermate 
controls. In contrast, FIL1R1KO mice showed improved cardiac function and reduced remodeling 
markers after MI compared with littermate controls. In conclusion, these data highlight a key role 
for the IL-1R1/cardiac fibroblast signaling axis in regulating remodeling after MI and provide support 
for the continued development of anti–IL-1 therapies for improving cardiac function after MI. 
Cardiomyocyte-derived IL-1α was not an important contributor to remodeling after MI in this model.
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be a key trigger for inflammation in the liver (9). Importantly, it has also been proposed that IL-1α release 
from necrotic cardiomyocytes acts in a similar manner, triggering the early inflammatory response post-
MI (10). This key role for IL-1α in inflammation post-MI has been supported by a recent murine study in 
which an IL-1α–specific blocking antibody reduced myocardial injury and improved cardiac function after 
experimental MI (11). In contrast to IL-1α, IL-1β is inactive until it undergoes inflammasome-mediated 
proteolytic processing prior to nonclassical secretion from cells in response to specific stimuli (12). In mice, 
cardiomyocytes express both IL-1α and IL-1β, whereas cardiac fibroblasts express IL-1β but not IL-1α (10).
Irrespective of  their differences in expression, synthesis, activation, and secretion, the biological effects 
of  both IL-1α and IL-1β are mediated through the same receptor, IL-1 receptor-1 (IL-1R1). Ligand binding 
to IL-1R1 stimulates its association with the IL-1 receptor accessory protein (IL-1RacP), which in turn 
recruits the MyD88 and IRAK4 signaling proteins to form a stable tetrameric signaling module in which 
all components are essential (13). The downstream functional effects of  IL-1 are mediated primarily via the 
MAP kinase (ERK, p38, JNK) and NF-κB signaling pathways, which are stimulated following recruitment 
of  further adaptor proteins and kinases to the core IL-1R1 signaling module (3, 13).
Studies of  IL-1R1 global KO mice have revealed a critical role for IL-1R1 in mediating cardiac myofibro-
blast accumulation, MMP expression, and fibrotic remodeling of  the infarcted heart (14–16). The beneficial 
effects observed in IL-1R1–KO mice were largely the result of  suppressed inflammation; however, direct 
effects on cardiac fibroblasts were also suggested (14). Nevertheless, the global nature of  these IL-1R1–KO 
models makes it difficult to evaluate the precise contribution of  IL-1 signaling in cardiac fibroblasts.
Taken together, these in vivo and in vitro studies suggest that interplay between IL-1α (released from 
damaged cardiomyocytes) and IL-1R1 activation (on cardiac fibroblasts) is critical in the early myocardial 
remodeling process post-MI. However, to date no studies to our knowledge have sought to directly evaluate 
the importance of  these interactions in vivo in a cell-specific context. The aim of  this study was to use cell 
type–specific KO mouse models to investigate the role of  cardiomyocyte IL-1α and fibroblast IL-1R1 in 
regulating cardiac remodeling post-MI.
Results
Cardiomyocyte-specific IL-1α KO does not affect cardiac function or remodeling after experimental MI. A cardiomyo-
cyte-specific IL-1α–KO mouse model was generated to evaluate the contribution of  cardiomyocyte-derived 
IL-1α to cardiac remodeling post-MI. Firstly, a floxed Il1a mouse was created in which exon 4 of  the Il1a 
gene was modified to be flanked by loxP sites (Figure 1A and Supplemental Figure 1A; supplemental 
material available online with this article; https://doi.org/10.1172/jci.insight.125074DS1). Floxed Il1a 
mice were then bred with mice expressing Cre recombinase under control of  the cardiomyocyte-specif-
ic Myh6 promoter to produce Cre-positive cardiomyocyte-specific IL-1α–KO (MIL1AKO) mice and con-
trol Cre-negative floxed littermates (Supplemental Figure 1B). Deletion PCR confirmed that Cre-positive 
MIL1AKO mice had the expected deletion within exon 4 of  the Il1a gene and that this was only apparent 
in heart tissue (Figure 1B). Mean Il1a mRNA expression levels in whole heart samples from control mice 
were relatively low and were further reduced in hearts from MIL1AKO mice (Figure 1D), reflecting Il1a 
gene deletion in the cardiomyocyte population of  the heart. Baseline cardiac characteristics in control 
(Cre-negative Il1afl/fl) and MIL1AKO (Cre-positive Il1afl/fl) mice were assessed by pressure-volume (P-V) 
conductance catheter analysis and showed no difference between groups (Supplemental Figure 2A). Basal 
expression levels of  remodeling genes (collagens and hypertrophy markers) were also similar for the 2 lines 
(Supplemental Figure 2B). Thus, Cre-induced deletion of  IL-1α in cardiomyocytes had no effect on the 
baseline cardiac phenotype of  the animals.
To determine the effect of  cardiomyocyte-specific IL-1α KO on post-MI function and remodeling, we 
used a permanent left anterior descending (LAD) coronary artery ligation model of  experimental MI. Male 
Cre-negative (control) and Cre-positive (MIL1AKO) littermates underwent LAD ligation at 10–12 weeks 
of  age (Figure 1C), and cardiac physiological measurements were obtained 4 weeks later by P-V conduc-
tance catheter analysis (Figure 1E). MI scarring was clearly visible in hearts obtained from animals that had 
undergone LAD ligation (Figure 2A).
As expected, control mice displayed overt cardiac dysfunction 4 weeks post-MI, as evidenced by 
reduced ejection fraction (EF), increased end-systolic volume (ESV), and increased end-diastolic volume 
(EDV) compared with sham animals (Figure 1E), with other parameters being unaffected (Supplemental 
Table 1). Importantly, no difference in post-MI cardiac function was observed between control mice and 
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MIL1AKO mice (Figure 1E and Supplemental Table 1), indicating that cardiomyocyte-derived IL-1α per 
se was not an important contributor to cardiac dysfunction post-MI.
Assessment of  gene expression in the infarct region 3 days post-MI by real-time quantitative 
reverse-transcription PCR (qRT-PCR) revealed increases in mRNA levels of  inflammatory genes (Il1b, 
Tnfa, Il6) and ECM regulatory genes (Mmp3, Mmp9, Tnc, Postn, Col1a1, Col3a1) and reduced mRNA for 
the myofibroblast differentiation marker Acta2 in MI hearts compared with sham hearts (Figure 1F). 
Importantly, there was no difference in expression levels of  these genes between control and MIL1A-
KO mice post-MI (Figure 1F). Histological analysis of  hearts 4 weeks post-MI revealed no obvious 
differences between control and MIL1AKO mice, with both showing thinning of  the LV free wall in the 
infarct area and scar tissue marked by ECM deposition (Figure 2B), in agreement with the functional 
and mRNA expression data.
Characterization of  fibroblast-specific IL-1R1–KO mouse model. Having ruled out a role for cardiomyo-
cyte-derived IL-1α in modulating cardiac remodeling post-MI, we proceeded to investigate the specific 
role of  the IL-1 receptor (IL-1R1) expressed by cardiac fibroblasts. Col1a2-CreER(T) mice have previ-
ously been used to induce Cre-lox-mediated deletion of  genes specifically in fibroblasts (17), including 
those in the heart (18–20), without affecting cardiomyocytes, endothelial cells, smooth muscle cells, 
progenitor cells, pericytes, or macrophages. We first developed a Col1a2-Cre-Il1r1fl/fl mouse line (see 
Supplemental Figure 3A for breeding strategy) to explore the effects of  fibroblast-specific IL1R1 dele-
tion on cardiac remodeling. However, this method was ineffective at reducing IL1R1 expression or 
activation in cardiac fibroblasts (data not shown), despite our previous success with this approach for 
deleting other genes (20). To overcome this problem, we adopted a modified strategy to generate a 
hemizygous mouse line with global deletion of  one Il1r1 allele in which the remaining allele was floxed. 
This approach is particularly useful for targeting genes whose heterozygous (+/–) KO does not cause a 
phenotype, as it maximizes the effect of  inducible KO of  the remaining allele (21).
Therefore, we first generated global IL-1R1+/– heterozygous mice and IL-1R1–/– KO mice (see Sup-
plemental Figure 3B for breeding strategy) to investigate the phenotypic effect of  monoallelic and bial-
lelic deletion of  Il1r1. As expected, primary cultures of  cardiac fibroblasts from heterozygous animals 
exhibited a 50% reduction in Il1r1 mRNA levels compared with wild-type mice, with no detectable 
expression in those from IL-1R1–KO mice (Figure 3A). The functional effect of  fibroblast IL1R1 KO 
was evaluated in cultured cardiac fibroblasts by measuring IL-1α responses, specifically kinase signal-
ing pathways, gene expression, and protein secretion. IL-1α stimulated the p38 and NF-κB signaling 
pathways (Figure 3B) and increased Il6, Mmp3, and Mmp9 mRNA expression (Figure 3C) and IL-6 and 
MMP-3 protein secretion (Figure 3D) to a similar extent in fibroblasts from wild-type and heterozygous 
mice, despite the latter expressing only half  the amount of  IL-1R1. Cardiac fibroblasts from IL-1R1–
KO mice did not respond to IL-1α stimulation (Figure 3, B–D), confirming full loss of  the receptor. 
Responses to TNF-α, a proinflammatory cytokine that activates similar signaling pathways and gene 
expression profiles to IL-1α but via a different receptor, were unaffected in cardiac fibroblasts from 
IL-1R1–KO mice (Figure 3, B and E). Together, these data establish that full biallelic deletion of  Il1r1 
is necessary to disrupt IL-1 responses in cardiac fibroblasts and that monoallelic deletion is ineffective.
We next generated hemizygous mice in which one Il1r1 allele was floxed and the other was delet-
ed (fl/–). These animals were crossed with heterozygous mice that expressed tamoxifen-inducible Cre 
Figure 1. Creation, characterization, and functional assessment of cardiomyocyte-specific IL-1α–KO mouse line (MIL1AKO). (A) Generation of floxed 
IL-1α (exon 4) mice (Il1afl/fl). Genetic targeting shows exon 4 flanked by loxP sites, positioned upstream of a lacZ/Neo resistance cassette, which is excised 
upon Flp recombination, resulting in the generation of Il1afl/fl allele. Cre recombinase leads to exon 4 deletion, generating IL-1 KO mice. (B) Genotyping 
showing exon 4 deletion of Il1a gene, with size markers (bp) to the left. Top: PCR analysis for Il1a exon 4 deletion (456 bp) in cardiac tissue from Cre-neg-
ative Il1afl/fl and Myh6-Cre–positive Il1afl/fl (MIL1AKO) mice. Bottom: PCR analysis for exon 4 deletion (456 bp) in various tissues in Cre-positive MIL1AKO 
mice, confirming cardiac-specific deletion. See Supplemental Table 3 for primer details. (C) Timeline showing experimental myocardial infarction (MI) 
induced by ligation of the left anterior descending (LAD) coronary artery and time points for collection of RNA, histology, and measurement of cardiac 
function by pressure-volume (P-V) conductance catheter. (D) qRT-PCR analysis of basal Il1a mRNA expression in hearts from control (Ctrl; Cre-negative 
Il1afl/fl) and MIL1AKO (MKO; Myh6-Cre–positive Il1afl/fl) mice. *P < 0.05 for effect of KO (unpaired t test, n = 4). (E) P-V conductance catheter data. Sham, 
mixed genotypes (n = 19); MI Ctrl, Cre-negative Il1afl/fl after MI (n = 19); MI MKO, Myh6-Cre–positive Il1afl/fl (MIL1AKO) after MI (n = 17). *P < 0.05; **P < 
0.01; ***P < 0.001; NS, not significant between the 2 MI groups (1-way ANOVA with Tukey post hoc). (F) qRT-PCR data showing relative mRNA levels of 
remodeling genes Il1b, Tnfa, Il6, Mmp3, Mmp9, tenascin C (Tnc), α-smooth muscle actin (Acta2), periostin (Postn), collagen Iα1 (Col1a1), and collagen IIIα1 
(Col3a1). Sham, mixed genotypes (n = 7); MI Ctrl, Cre-negative Il1afl/fl after MI (n = 5); MI MKO, Myh6-Cre–positive Il1afl/fl (MIL1AKO) after MI (n = 5). *P < 
0.05; **P < 0.01; ***P < 0.001 versus sham; NS, not significant between MI groups (1-way ANOVA with Tukey post hoc).
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recombinase [CreER(T)] under the control of  the fibroblast-specific 
Col1a2 promoter (Figure 4A) to generate Col1a2-CreER(T)-Il1r1fl/– 
mice, a line we named FIL1R1KO (see Supplemental Figure 3C 
for breeding strategy). Example genotyping results are shown in 
Supplemental Figure 4. Mice were injected with tamoxifen at 12 
days of  age to induce Cre-loxP–-mediated deletion, and hearts iso-
lated after a further 4–8 weeks for analysis. The efficiency of  fibro-
blast-specific deletion of  IL-1R1 was confirmed in primary cultures 
of  cardiac fibroblasts by qRT-PCR. Cells from FIL1R1KO mice 
had a mean 75% reduction in basal Il1r1 mRNA levels compared 
with cells from Cre-negative Il1r1fl/– littermate control mice (Fig-
ure 4B), indicating that full biallelic deletion of  Il1r1 had occurred 
in response to tamoxifen in approximately 75% of  cardiac fibro-
blasts. The functional effect of  IL-1R1 deletion was evidenced by a 
marked reduction in the activation of  the p38 and NF-κB signaling 
pathways in response to IL-1α, without affecting TNF-α–induced 
signaling (Figure 4C). Moreover, mean IL-1α–induced Il6, Mmp3, 
and Mmp9 mRNA expression was reduced by 65%–75% in fibro-
blasts cultured from FIL1R1KO hearts compared with cells from control littermate hearts (Figure 4D), in 
close agreement with the extent of  IL1R1 knockdown (Figure 4B). Similar changes were noted for protein 
secretion; for example, mean IL-1α–induced IL-6 secretion was reduced by > 50% in cardiac fibroblasts 
from FIL1R1KO mice (Figure 4E).
Fibroblast-specific IL-1R1 KO improves cardiac remodeling after experimental MI. Having confirmed func-
tional and sustained knockdown of  IL-1R1 in cardiac fibroblasts isolated from tamoxifen-treated FIL-
1R1KO mice, we next investigated the in vivo effect of  fibroblast-selective IL-1R1 deletion on cardiac 
function after experimental MI (Figure 5A). Male Cre-negative (control) and Cre-positive (FIL1R1KO) 
littermates were injected with tamoxifen at 12 days of  age for 5 consecutive days and underwent perma-
nent LAD coronary artery ligation surgery at 10–12 weeks of  age. Sham control animals (pooled Cre-neg-
ative and Cre-positive) were not injected with tamoxifen. There were no differences in baseline cardiac 
characteristics between Cre-positive and Cre-negative mice (Supplemental Figure 5). Physiological mea-
surements were obtained 4 weeks after LAD ligation by P-V catheter analysis, before hearts were analyzed 
for histological and molecular markers of  remodeling. P-V analysis (Figure 5B and Supplemental Table 2) 
revealed significantly reduced EF in control mice 4 weeks post-MI compared with sham (48% versus 61% 
respectively; P = 0.02), but, importantly, EF was only partially reduced to 56% in FIL1R1KO mice post-
MI and was not significantly different than that of  sham controls. dPdtmax (an indicator of  contractility) 
was also significantly decreased in control MI mice compared with sham animals but was less affected 
in FIL1R1KO mice; the difference in dPdtmax between post-MI FIL1R1KO and sham animals was not 
significant. Similar, nonsignificant trends were observed with ESV and EDV (Figure 5B and Supplemental 
Table 2). End-systolic pressures were significantly reduced in MI mice of  both genotypes compared with 
sham animals, whereas other cardiac parameters and arterial blood pressure were not significantly differ-
ent between the 3 groups (Supplemental Table 2).
The impact of  fibroblast-selective IL-1R1 deletion on specific molecular markers of  cardiac 
remodeling was assessed by qRT-PCR of  whole ventricle mRNA samples taken from hearts used 
for P-V analysis (i.e., 4 weeks after LAD ligation). Nine genes were studied that included markers of  
ECM synthesis (Col1a1, Col3a1), ECM degradation (Mmp3, Mmp9), myofibroblast activation (Acta2), 
mechanical activation (Tnc, Il6), and cardiomyocyte hypertrophy (Myh7, Nppa). Significant increases 
Figure 2. Effect of cardiomyocyte-specific IL-1α deletion on cardiac 
remodeling after MI. (A) Representative images of sham and myocardial 
infarction (MI) hearts at the end of the experimental period (4 weeks after 
surgery). Sham, mixed genotypes; MI Ctrl, Cre-negative Il1afl/fl after MI; MI 
MIL1AKO, Myh6-Cre–positive Il1afl/fl after MI (n = 5). Dashed line, infarcted 
area. (B) Representative photomicrographs of histological sections of 
hearts stained with Miller’s elastic van Gieson. Yellow stain, muscle; pink, 
collagen; purple, elastin. Scale bars: 700 μm.
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in Col1a1 (1.7-fold increase; P < 0.05), Col3a1 (3.2-fold; P < 0.001), Mmp3 (2.5-fold; P < 0.01), and Tnc 
(2.1-fold; P < 0.01) mRNA levels were observed in control hearts after MI compared with sham hearts 
(Figure 5C). By comparison, the expression levels of  4 of  these genes was markedly less in hearts after 
MI from FIL1R1KO mice [Col1a1 (1.3-fold increase), Col3a1 (1.8-fold; P < 0.05 versus control MI), 
Mmp3 (1.7-fold), Tnc (1.3-fold)] and, with the exception of  Col3a1, were not significantly different from 
sham levels (Figure 5C).
Histological staining was performed on hearts 5 days (Figure 6) or 6 weeks (Figure 7) after MI. 
In control mice, granulation tissue was evidenced after 5 days by inflammatory cell infiltration (Fig-
ure 6, H&E) and marked tenascin C expression was also observed (Figure 6), with a small amount 
of  collagen expression (Figure 6, MVG). After 6 weeks, control mice had evidence of  ventricular 
wall thinning (Figure 7) and more collagen deposition (Figure 7, MVG), with very little tenascin 
C expression (Figure 7). All these changes were more pronounced in control mice compared with 
FIL1R1KO mice (Figures 6 and 7).
Figure 3. Effect of global IL-1R1 KO on cardiac fibroblast responses to inflammatory cytokines. (A) qRT-PCR data showing basal IL-1 receptor 1 (Il1r1) 
mRNA levels in cardiac fibroblasts cultured from wild-type (+/+), IL-1R1 heterozygote (+/–), and IL-1R1–KO (–/–) mice (all n = 4). *P < 0.05; ***P < 0.001 ver-
sus wild-type (1-way ANOVA with Tukey post hoc). (B) Cardiac fibroblasts were exposed to vehicle control (C), 1 ng/ml IL-1α (IL1), or 10 ng/ml TNF-α (TNF) 
for 30 minutes. Immunoblotting was used to measure activation of p38 MAP kinase (phosphorylation; p-p38) or activation of IκB-α (proteasome-mediat-
ed degradation). β-Actin, loading control. Numbers under blots represent densitometric analysis relative to β-actin normalized to lane 1. Representative of 
2 separate experiments. (C and D) Cardiac fibroblasts were treated with vehicle (white boxes) or 1 ng/ml IL-1α (colored boxes) for 6 hours before measuring 
mRNA levels of Il6, Mmp3, and Mmp9 by qRT-PCR (C) and protein secretion by ELISA (D). (E) Cardiac fibroblasts were treated with vehicle (white boxes) or 
10 ng/ml TNF-α (colored boxes) for 6 hours before measuring Mmp9 mRNA levels by qRT-PCR. *P < 0.05; **P < 0.01; ***P < 0.001, NS, not significant for 
effect of cytokine. ###P < 0.001; ##P < 0.01, NS, not significant for effect of IL-1R1 KO (2-way ANOVA with Bonferroni post hoc). n = 4 per genotype.
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Discussion
We used two potentially novel cell-specific KO mouse models to investigate the role of  cardiomyo-
cyte-derived IL-1α and the cardiac fibroblast IL-1 receptor, IL-1R1, in remodeling of  the heart after 
MI. The principal conclusion of  our study was that fibroblast-specific deletion of  IL-1R1 was cardi-
oprotective following MI, whereas cardiomyocyte-specific deletion of  IL-1α had no effect. Our data 
with FIL1R1KO mice suggest that fibroblast IL-1R1 signaling is a significant driver of  detrimental car-
diac remodeling after MI. In vitro studies have revealed that cardiac fibroblasts adopt a proinflamma-
tory, proangiogenic, promigratory, ECM-degrading, nondifferentiated phenotype in response to IL-1 
(3). Our in vivo observations suggest that these acute effects of  IL-1 on cardiac fibroblasts early after 
MI contribute to longer-term adverse cardiac remodeling that is detrimental to cardiac function. These 
data support ongoing strategies aimed at inhibiting IL-1 or its receptor to improve cardiac function 
after MI (6–8).
Figure 4. Effect of tamoxifen-induced fibroblast-specific IL-1R1 knockdown on cardiac fibroblast responses to 
IL-1. (A) Schematic showing loxP-targeted Cre-mediated deletion of exon 5 within the IL-1 receptor-1 gene, Il1r1. (B–
E) Fibroblast cultures were established from hearts of Cre-negative (Ctrl; n = 7) and Cre-positive (fibroblast-specific 
IL-1 receptor 1 KO [FIL1R1KO]; n = 5) hemizygous Il1r1fl/– mice 6 weeks after tamoxifen injection. (B) qRT-PCR analysis 
of basal Il1r1 mRNA expression in cardiac fibroblasts from Ctrl and FIL1R1KO mice. **P < 0.01 for effect of KO 
(unpaired t test). (C) Cardiac fibroblasts with different genotypes were exposed to vehicle (control, C), IL-1α (IL-1), 
or TNF-α (TNF) for 30 minutes before immunoblotting to measure activation of p38 MAP kinase (phosphorylation; 
p-p38) or activation of IκB-α (proteasome-mediated degradation). β-Actin, loading control. Plots to the right depict 
densitometric analysis relative to β-actin normalized to lane 1 for control (white symbols) or IL-1 treatment (colored 
symbols). n = 2. (D and E) Cardiac fibroblasts were treated with vehicle (white boxes) or 1 ng/ml IL-1α (colored boxes) 
for 6 hours before measuring mRNA levels of Il6, Mmp3, and Mmp9 by qRT-PCR (D), and IL-6 secretion by ELISA (E). 
***P < 0.001; **P < 0.01; *P < 0.05, NS, not significant for effect of IL-1; ##P < 0.01; #P < 0.05 for effect of IL-1R1 KO 
(2-way ANOVA with Bonferroni post hoc).
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Figure 5. Effect of fibroblast-specific IL-1R1 deletion on cardiac function and remodeling genes 4 weeks after MI. (A) Experimental timeline 
showing timing of tamoxifen injection and experimental myocardial infarction (MI) induced by ligation of the left anterior descending (LAD) coronary 
artery, as well as the timing for histology, collection of RNA, and measurement of cardiac function by pressure-volume (P-V) conductance catheter. 
(B) P-V conductance catheter data. Sham, mixed genotypes, no tamoxifen treatment (n = 18); MI Ctrl, tamoxifen-treated Cre-negative Il1r1fl/– after MI 
(n = 11); MI FKO, tamoxifen-treated Cre-positive Il1r1fl/– (FIL1R1KO; fibroblast-specific IL-1 receptor 1 KO) after MI (n = 11). *P < 0.05 versus sham. (C) 
qRT-PCR data showing relative mRNA levels of remodeling genes collagen Iα1 (Col1a1), collagen IIIα1 (Col3a1), Mmp3, Mmp9, α-smooth muscle actin 
(Acta2), tenascin C (Tnc), Il6, β-myosin heavy chain (Myh7), and atrial natriuretic factor (Nppa). Sham, mixed genotypes, no tamoxifen treatment (n 
= 8); MI Ctrl, tamoxifen-treated Cre-negative mice after MI (n = 8); MI FKO, tamoxifen-treated FIL1R1KO mice after MI (n = 8). *P < 0.05; **P < 0.01; 
***P < 0.001 versus sham; #P < 0.05 versus MI Ctrl (1-way ANOVA with Tukey post hoc).
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Role of  IL-1α. Cardiomyocyte-specific overexpres-
sion of  human IL-1 induces cardiac hypertrophy in mice 
(22). Moreover, it has been proposed by Lugrin and col-
leagues that cardiomyocyte-derived IL-1α is important 
for stimulating the early inflammatory response after MI 
(10). On the contrary, we observed no difference in cardi-
ac function or expression of  remodeling genes after MI in 
a cardiomyocyte-specific IL-1α–KO mouse (MIL1AKO) 
compared with control mice, suggesting that cardiomyo-
cyte-derived IL-1α is not an essential player in this process. 
It is worth noting several differences between our study 
and that of  Lugrin et al. (10). First, we used a cardiomyo-
cyte-specific IL-1α–KO mouse, whereas their study used 
global IL-1α–KO mice, so it is possible that the effects that 
were observed therein were due to IL-1α deletion in non-
myocyte cells (e.g., endothelial cells, fibroblasts, inflam-
matory cells), which together account for 70% of  cells in 
the murine heart (23). Second, the experimental MI model 
used in Lugrin’s study (10) was an ischemia/reperfusion 
model of  MI, as opposed to the permanent LAD ligation 
model we used. Although the ischemia/reperfusion mod-
el more closely resembles the clinical scenario where most 
patients undergo revascularization, the permanent occlu-
sion model is particularly useful for understanding direct 
mechanisms without the confounding element of  reperfu-
sion. We chose the permanent occlusion model based on previous studies showing that interference of  IL-1 
signaling had favorable effects in both nonreperfusion (16) and reperfusion models (10, 14). Finally, Lugrin 
et al. (10) did not evaluate longer-term functional endpoints, with all measurements being taken immediate-
ly after the reperfusion period (2 hours). The increase in IL-6, one of  the markers studied, was reduced in 
global IL-1α–KO mice after the 2-hour reperfusion period (10). In contrast, in our study, Il6 mRNA levels 
remained significantly elevated 3 days after permanent LAD occlusion and were not affected by cardiomyo-
cyte-specific IL-1 deletion, indicating that there was no long-term effect on inflammation.
Our results do not preclude an important role for IL-1α per se, and, indeed, there is recent evidence 
that cardiac IL-1α is important in cardiac remodeling after MI, as administration of  an IL-1α–neutralizing 
antibody reduced infarct size and preserved LV systolic function in an ischemia/reperfusion model of  MI 
(11). Although we observed that basal cardiac Il1a mRNA levels were very low, and were further reduced 
in MIL1AKO mice, IL-1α release could still occur in our model in nonmyocyte cells, including endothelial 
cells, fibroblasts, and macrophages, all of  which may contribute to cardiac IL-1α levels after MI.
Role of  IL-1β. Although our study did not directly investigate the contribution of  IL-1β to remodeling 
after MI, our data with the FIL1R1KO mouse may indicate a role for IL-1β acting on fibroblast IL-1R1. 
Indeed, such a role is supported by mouse and rat studies in which anti–IL-1β–neutralizing antibodies 
administered after MI improve cardiac function and limit adverse remodeling (24, 25). IL-1β is produced by 
multiple cardiac cell types (26) and can directly promote adverse cardiac remodeling (4).
Clinical relevance. Therapeutic IL-1 blockade has now been evaluated in several cardiovascular clinical 
trials (reviewed in refs. 6–8). Initially, a number of  small-scale trials investigated the effect of  anakinra, 
Figure 6. Effect of fibroblast-specific IL-R1 deletion on histolog-
ical markers of cardiac remodeling 5 days after MI. Representa-
tive photomicrographs of adjacent histological sections from con-
trol and fibroblast-specific IL-1 receptor 1–KO (F1L1RKO) hearts. 
Left column: H&E staining showing inflammatory infiltrates and 
interstitial cells in the infarct zone. Middle column: Miller’s elas-
tic van Gieson (MVG) staining showing elastin (blue) and collagen 
(pink) staining; muscle tissue is stained yellow. Right column: 
Tenascin C staining (brown). Scale bars: 500 μm.
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a recombinant form of  the IL-1 receptor antagonist, on 
inflammation and cardiac remodeling in stable-STEMI 
and non-STEMI patients (27, 28) and reported that IL-1 
inhibition reduced inflammation after MI but had little 
effect on cardiac function in the longer term. This may 
relate to the relatively mild inflammatory phenotype 
in these patient cohorts compared with general STEMI 
patients, in whom IL-1 blockade was more effective (29). 
A more recent anakinra trial (D-HART2) reported that 
IL-1 blockade did not improve cardiorespiratory fitness 
in obese HF patients with preserved EF, although mark-
ers of  systemic inflammation and myocardial strain were 
reduced (30). In comparison to general IL-1 blockade with 
anakinra, the recent CANTOS trial used an IL-1β–specif-
ic neutralizing antibody (canakinumab) and reported a 
reduction in cardiovascular events independent of  lipid 
levels (31), with a suggestion that the cardioprotective 
effects extended beyond new atherothrombotic events. 
Thus, there is gathering momentum for the use of  target-
ed anti–IL-1 therapies for improving outcome after MI, at 
least in some patient populations.
Study limitations. Although our study provided evi-
dence for a role of  fibroblast IL-1R1 in driving adverse 
cardiac remodeling, it remains unclear whether IL-1α 
or IL-1β (or both) is the most important stimulus. Our 
results with MIL1AKO mice ruled out a role for car-
diomyocyte-derived IL-1α, but other cellular sources of  
IL-1α were not explored. Future studies investigating selective IL-1α KO in other cardiac cell types 
(fibroblasts, endothelial cells, macrophages) will be required to explore this further. Similarly, global 
or cell-specific IL-1β KO mice would be helpful in determining the precise role of  IL-1β in this set-
ting. We used a permanent LAD ligation model of  MI; investigations with an ischemia/reperfusion 
model of  MI would be important to confirm our data in a more clinically appropriate model. We did 
not evaluate the area at risk in our MI models, although this might have been useful to understand 
the underlying mechanisms for cardioprotection in FIL1R1KO mice. Although we studied specific 
features of  remodeling by quantifying expression levels of  specific genes, and provided representative 
histological images, a more in-depth quantitative analysis of  inflammation and fibrosis using support-
ive methodologies (e.g., flow cytometry and hydroxyproline incorporation, respectively) would have 
strengthened our conclusions. Prolonged cardiomyocyte-specific Cre expression has been reported to 
result in modest cardiac dysfunction, fibrosis, and hypertrophy in 6-month-old Myh6-Cre mice (32) but 
not in 3-month-old mice (32, 33). The MIL1AKO mice used in the current study were 10–12 weeks of  
age at the time of  surgery, and, although not directly addressed in our study, it is therefore unlikely that 
age-dependent Cre cardiotoxicity influenced the data.
Conclusion. Our data highlight the importance of  the IL-1/cardiac fibroblast signaling axis in regu-
lating remodeling after MI and provide support for the continued development of  anti–IL-1 therapies 
for improving cardiac function after MI.
Figure 7. Effect of fibroblast-specific IL-R1 deletion on histolog-
ical markers of cardiac remodeling 6 weeks after MI. Represen-
tative photomicrographs of adjacent histological sections from 
control and fibroblast-specific IL-1 receptor 1–KO (F1L1RKO) hearts. 
Left column: H&E staining showing inflammatory infiltrates and 
interstitial cells in the infarct zone. Middle column: Miller’s elastic 
van Gieson (MVG) staining showing elastin (blue) and collagen 
(pink) staining; muscle tissue is stained yellow. The area of ven-
tricular thinning is indicated with an arrowhead. Right column: 
Tenascin C staining (brown). Scale bars: 500 μm.
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Methods
Animal welfare
Mice were maintained in individually ventilated cages at 21°C, 50%–70% humidity, and 12/12-hour-
light/dark cycle, with Pure-o’Cel paper bedding (Datesand) and ad libitum access to water and RM1 diet 
(Special Diets Services).
Mouse models
Floxed mice. Floxed Il1a (exon 4) mice were created as follows. Il1atm1a(EUCOMM)Wtsi embryonic stem cells (34) 
were purchased from the European Mouse Mutant Cell Repository. Cells from clone EPD0822-4-H02 
were prepared for microinjection according to a previously published protocol (35) with minor modifica-
tions. Briefly, cells were cultured in KO-DMEM plus KOSR medium plus 2i (MEK inhibitor and GSK3 
inhibitor) on a gelatin-coated (0.1% gelatin in phosphate-buffered saline) cell culture dish maintained 
under standard culture conditions (37°C, 5% CO2, humidified). Culture medium was changed daily, and 
cells were passaged when 75%–80% confluent using accutase (Sigma-Aldrich) to dissociate them. Cells 
were passaged no more than 3 times and were transferred to media without 2i reagents for 24 hours 
before microinjection. Cells were then microinjected into 4–8 cell B6N-Tyrc–Brd/BrdCrCrl embryos. Sur-
viving embryos were surgically implanted into the oviduct of  day 0.5 postcoitum pseudopregnant mice. 
Resulting black/white C57BL/6N chimeras were backcrossed onto C57BL/6N wild-type mice to assess 
germline penetrance. Potential founder mice were screened by PCR for LacZ, Neo, and LoxP sites. This 
line was further crossed with C57BL/6N-Tg(CAG-Flpo)1Afst/Mmucd mice from the Mutant Mouse 
Resource & Research Centers. The FLP recombinase expression provided by this line resulted in a “con-
ditional ready” (i.e., floxed) Il1atm1c(EUCOMM)Wtsi allele, in which exon 4 is flanked by loxP sites. Floxed Il1r1 
(exon 5) mice have been described previously (36) and were provided in-house.
Cre-expressing mice. Cardiomyocyte-specific Myh6-Cre mice (stock no. 011038) and PGK-Cre global del-
eter mice (stock no. 020811) were obtained from The Jackson Laboratory. Fibroblast-specific tamoxifen-in-
ducible Col1a2-Cre-ER(T) mice have been well characterized (17, 37) and were provided in-house.
Breeding of  cardiomyocyte-specific and fibroblast-specific KO mice. The breeding strategy to obtain cardio-
myocyte-specific IL-1α–KO mice (Supplemental Figure 1B) involved crossing homozygous Il1afl/fl mice 
with heterozygous Myh6-Cre mice to generate Myh6-Cre-Il1afl/fl mice. When these were backcrossed with 
Il1afl/fl mice, Cre-positive cardiomyocyte-specific IL-1α–KO mice (MIL1AKO mice) and Cre-negative 
floxed littermates (control) were produced.
For investigating IL-1R1 in cardiac fibroblasts, a tamoxifen-inducible fibroblast-specific IL-1R1–KO 
mouse line [Col1a2-CreER(T)-Il1r1fl/fl] was initially established on a C57BL/6 background by crossing 
Col1a2-CreER(T) mice with Il1r1fl/fl mice (Supplemental Figure 3A). Global IL-1R1–KO mice were subse-
quently established by crossing female PGK-Cre mice with male Il1r1fl/fl mice on a C57BL/6 background 
(Supplemental Figure 3B). Finally, a tamoxifen-inducible fibroblast-specific IL-1R1 hemizygous KO mouse 
line (FIL1R1KO) [Col1a2-CreER(T)-Il1r1fl/–] was established by crossing heterozygous Col1a2-Cre-ER(T) 
mice with Il1r1fl/fl mice on a C57BL/6 background (Supplemental Figure 3C).
Tamoxifen-inducible Cre activation
For the fibroblast-targeted studies, control (Cre-negative Il1r1fl/–) and FIL1R1KO mice were injected with 
tamoxifen dissolved in corn oil (100 mg/kg/d i.p. for 5 consecutive days) at 12 days of  age to induce 
CreER(T) activity and facilitate Cre/loxP-mediated deletion in Cre-positive fibroblasts.
Genotyping PCR
For routine genotyping, DNA was extracted from lysed ear notch/tissue samples using tail lysis buffer 
supplemented with proteinase K as described previously (20), and endpoint PCR was performed with spe-
cific primer pairs (Supplemental Table 3) before resolution by agarose gel electrophoresis (Figure 1B, Sup-
plemental Figure 1A, and Supplemental Figure 4). Routine genotyping was subsequently outsourced to 
Transnetyx for automated analysis.
Endpoint PCR was also used to confirm cardiomyocyte-specific deletion of  Il1a exon 4 in whole 
heart tissue and fibroblast-specific deletion of  Il1r1 exon 5 in cultured cardiac fibroblasts using specific 
primer sets (Supplemental Table 3).
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Experimental MI model
A permanent LAD coronary artery ligation model of  experimental MI was performed on 5% isoflu-
rane-anesthetized male mice (10–12 weeks of  age), as we described previously (38). Following intuba-
tion, mice were ventilated at a tidal volume of  140 μl and a respiratory rate of  120/minute with 1.5% 
isoflurane and 100% oxygen. The LAD was ligated at the edge of  the left atrium using 8-0 prolene suture, 
and occlusion was confirmed by observing the pallor of  the anterior LV wall.
For cardiomyocyte-targeted mice, LAD ligation was performed on Cre-positive (MIL1AKO) and 
Cre-negative (control) littermates. For fibroblast-targeted mice, LAD ligation was performed on Cre-positive 
(FIL1R1KO) and Cre-negative (control) littermates that had been injected with tamoxifen at 12 days of  age. 
Sham-operated animals (no tamoxifen treatment) underwent a similar surgical procedure without tying the 
ligature. In order to keep the number of  animals used to a minimum, sham data were combined from the 
2 different genotypes (Cre-positive and Cre-negative), which showed no differences in baseline phenotype.
Measurement of cardiac function
Physiological measurements of  cardiac function were obtained by Millar conductance P-V catheter analy-
sis, as we have described in full previously (20, 39). The investigator performing the P-V measurements was 
blinded to the genotype of  the animals.
Histology
Hearts were extracted at various time points and fixed in 4% paraformaldehyde before paraffin wax embed-
ding. Tissue sections (5 μm) were stained as we described previously with Miller’s elastic van Gieson 
(MVG) stain (40) or with antibodies for tenascin-C (Santa Cruz Biotechnology, sc-8694) (38). Composite 
tiled images were prepared from individual photomicrographs so that cross-sections through the whole 
heart could be observed.
Real-time qRT-PCR
RNA was purified from cells or snap-frozen heart tissue, and cDNA synthesis was performed as described 
previously (20). Real-time qRT-PCR was undertaken using an ABI-7500 System with specific TaqMan 
primer/probe sets (Applied Biosystems) for detecting Acta2 (Mm00725412_s1), Col1a1 (Mm00801666_g1), 
Col3a1 (Mm01254476_m1), Gapdh (Mm99999915_g1), Il1a (Mm99999060_m1), Il1b (Mm00434228_m1), 
Il1r1 (Mm01226961), Il6 (Mm00446190_m1), Mmp3 (Mm00440295_m1), Mmp9 (Mm00442991_m1), Myh7 
(Mm00600555_m1), Nppa (Mm01255747_g1), Postn (Mm01284919_m1), Tnc (Mm00495662_m1), and 
Tnfa (Mm00443258_m1). Data are expressed relative to Gapdh mRNA expression using the 2–ΔCT method.
Cardiac fibroblast culture
Cardiac fibroblasts were cultured from mouse hearts by a collagenase digestion method, as we 
described previously (20, 41). Experiments were performed in serum-free medium using early passage 
(P0 or P1) cells.
Immunoblotting
Immunoblotting was performed as described previously (42) using Cell Signaling Technology antibodies 
for phospho-p38 (product 9211) and IκB-α expression (product 9242). β-Actin expression (loading control) 
was detected with anti-β actin antibody (Abcam, ab8226). Horseradish peroxidase–conjugated second-
ary antibodies and enhanced chemiluminescence detection reagent were from GE Healthcare. Blots were 
imaged using the G:BOX gel doc system (Syngene), and band intensities were quantified using GeneTools 
software (Syngene) (Figure 1B, Supplemental Figure 1A, and Supplemental Figure 4).
Statistics
Statistical analyses were conducted using GraphPad Prism 7.01 Software. Unless stated otherwise, data 
are mean ± SEM. Box-and-whisker plots illustrate median, 25th/75th percentiles, and minimum/max-
imum. The n value represents the number of  separate animals or the number of  cell cultures from 
separate hearts (i.e., biological replicates). Data were analyzed by 2-tailed t test, 2-way ANOVA (with 
Bonferroni post hoc), or 1-way ANOVA (with Tukey post hoc), as appropriate. A P value of  less than 
0.05 was considered significant.
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